GGrantIndex
← Leaderboards

Fred D Lublin

Mount Sinai School Of Medicine Of Nyu

$22,560,310
Attributed
$23,293,661
Total exposure
4
Grants
3
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $20.2M · FY200522
$25M$18.8M$12.5M$6.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22

Funding mix

By agency

NIH$68,017,524 · 5

By mechanism

U01$63,823,863 · 2
R01$3,946,235 · 2
R21$247,426 · 1

Top collaborators

Most similar at Mount Sinai School Of Medicine Of Nyu

Same institution · by research overlap

Others in their field

Top investigators on “Multiple Sclerosis

Research focus

Multiple SclerosisClinical TrialsMagnetic Resonance ImagingFollow-UpBaseDisabilityTherapeutic AgentsCombined Modality TherapyEnrollmentFunctional DisorderDisease ProgressionCognitiveCognitive TestingFootGrantDesignAxonal DegenerationDiffusionInflammationCorpus CallosumBrainClinical ManagementAffectCopolymer 1

Grant awards (21)

MRI predictors of disease and disability progression in African Americans with multiple sclerosis$518,697
R01 · FY2022 · NS · contact PI
MRI predictors of disease and disability progression in African Americans with multiple sclerosis$643,285
R01 · FY2020 · NS · contact PI
Examining the role of brain sodium content in multiplesclerosis using MRI$364,035
R01 · FY2020 · NS · contact PI
MRI predictors of disease and disability progression in African Americans with multiple sclerosis$653,611
R01 · FY2019 · NS · contact PI
Examining the role of brain sodium content in multiplesclerosis using MRI$519,901
R01 · FY2019 · NS · contact PI
MRI predictors of disease and disability progression in African Americans with multiple sclerosis$663,940
R01 · FY2018 · NS · contact PI
Examining the role of brain sodium content in multiplesclerosis using MRI$582,766
R01 · FY2018 · NS · contact PI
Extension of Combination Therapy for Multiple Sclerosis$249,999
U01 · FY2012 · NS · contact PI
Extension of Combination Therapy for Multiple Sclerosis (eCombiRx)$249,999
U01 · FY2012 · NS · contact PI
Extension of Combination Therapy for Multiple Sclerosis (eCombiRx)$250,001
U01 · FY2011 · NS · contact PI
Extension of Combination Therapy for Multiple Sclerosis$250,001
U01 · FY2011 · NS · contact PI
Extension of Combination Therapy for Multiple Sclerosis$8,500,000
U01 · FY2010 · NS · contact PI
Extension of Combination Therapy for Multiple Sclerosis (eCombiRx)$8,500,000
U01 · FY2010 · NS · contact PI
Extension of Combination Therapy for Multiple Sclerosis$10,100,000
U01 · FY2009 · NS · contact PI
Extension of Combination Therapy for Multiple Sclerosis (eCombiRx)$10,100,000
U01 · FY2009 · NS · contact PI
Combination Therapy in Multiple Sclerosis$9,090,524
U01 · FY2008 · NS · contact PI
Combination Therapy in Multiple Sclerosis$1
U01 · FY2007 · NS · contact PI
Combination Therapy in Multiple Sclerosis$5,698,773
U01 · FY2006 · NS · contact PI
Combination Therapy in Multiple Sclerosis$3,834,565
U01 · FY2005 · NS
Combination Therapy in Multiple Sclerosis$7,000,000
U01 · FY2003 · NS
Combination Therapy in Multiple Sclerosis$247,426
R21 · FY2001 · NS